Her lawsuit claims the drugmaker failed to warn patients about the risk of major gastrointestinal side effects
Most active users also expect short-term treatment: 69% have used GLP-1 weight loss medications for fewer than two years, and over half plan to stop within two more years
GLP-1R agonists in obesity management GLP-1R agonists, such as semaglutide, liraglutide, and tirzepatide, have gained prominence in the treatment of obesity
Some individuals lose a lot of weight with semaglutide but see little change when they switch to tirzepatide
Discussion In this study, we applied DMRS, FDG-PET, and fMRI to explore the physiological role of GLP-1R in mouse brain glucose metabolism, metabolic homeostasis, and functional connectivity